Who gets better? Growth hormone at getgoodpeptides
Getting a hormone to rise is an interesting start. At the follow-up visit, I want an answer about what improved and whether it lasted.
After tesamorelin stopped
The end of the tesamorelin study is where I began. In a 52-week programme in adults with HIV and abdominal fat accumulation, visceral fat reduction was sustained at approximately 18% over the year. When treatment stopped, visceral fat reaccumulated. That last observation changes the meaning of the success without erasing it.
A benefit can be valuable while treatment continues. Still, I distrust “good” when it swallows the conditions: good for whom, measured how, and at which visit? Here the participants had HIV-associated lipodystrophy, and the outcome concerned fat deep inside the abdomen. A general promise of getting leaner would lose both the population and the follow-up.
That is the question behind getgoodpeptides. Four compounds can stimulate growth hormone, yet their experiments end in very different places: a height measurement, a blood sample, a tolerated meal, an abdominal-fat measurement. The endings deserve as much curiosity as the mechanisms. The tesamorelin follow-up is a useful place to start.
Growth hormone secretagogue peptides
A secretagogue prompts a gland to release something. In this case, the pituitary releases growth hormone, or GH; one downstream signal is insulin-like growth factor 1, IGF-1. The review of GHRH and its analogues explains how these signals connect, and why altering a receptor can change hormone release.
Sermorelin, CJC-1295 and tesamorelin act at the receptor for growth-hormone-releasing hormone, GHRH. Ipamorelin uses the ghrelin receptor, GHS-R1a. Its selective GH response in rat cells, rats and swine is a striking piece of pharmacology. Those experiments were acute and preclinical. Their precision makes the next question more interesting: which useful outcome followed?
GH axis peptides and GHRH receptor agonist peptides are convenient groupings. The family resemblance does less to answer that question than an individual study. The comparison puts their receptors, populations and results together.
The participants and the measurements
For sermorelin, the unusually concrete result is accelerated height growth in prepubertal children with GH deficiency. For CJC-1295 DAC, it is GH and IGF-1 elevation lasting for days in healthy adults. For ipamorelin, the published bowel-resection trial missed its primary endpoint. Tesamorelin has pooled randomized trials of visceral fat reduction in HIV-associated lipodystrophy.
I give the height and fat measurements more weight when judging an improvement in those conditions, because they reach beyond a hormone concentration. That preference leaves plenty of room to admire the chemistry. CJC-1295’s albumin attachment is ingenious; its early human studies simply leave a different set of questions open.
Follow whichever result prompted the visit: CJC-1295 research, sermorelin and growth, ipamorelin’s animal and human findings, or tesamorelin and visceral fat.
Everyday expectations
Community accounts of ipamorelin, CJC-1295 and sermorelin describe deeper sleep, recovery after exercise and gradual changes in appearance. Other accounts describe puffiness, tingling, headaches or little noticeable change. These are anecdotal accounts, not clinical evidence; their appeal cannot establish which compound caused an effect or how often it occurs.
I understand why feeling rested sounds more compelling than a serum result. A convincing trial of that everyday benefit would be welcome. Until then, the questions page deals with sleep claims, combinations and the difference between a molecule’s half-life and the duration of a benefit. This site offers research commentary, not medical advice or a plan for taking peptides.